The president has visited the pharmaceutical facilities, where she has learned the details of this investment until 2030 to increase its production capacity and consolidate the region as a global leader in the biopharmaceutical sector.
This project «will allow doubling the volume of drug production in the plant, create 75 new jobs, and also do so in specific profiles in robotics, artificial intelligence, analysis laboratory, logistics, or health sciences,» added the head of the regional government. For its development, the company has collaborated with the regional foreign investment attraction agency Invest in Madrid.
According to Díaz Ayuso, «with everyone’s work, the Community of Madrid has become a global hub for biopharmaceutical innovation. And companies like Lilly are essential in all of this, always serving medicine and life.»
Currently, this center is the only one of Lilly outside the United States that supplies medications worldwide and is second in clinical trials volume. It covers over 40,000 square meters and employs over 800 people.
Its presence in Spain dates back over 60 years, making significant investments in R&D, with 15 million euros allocated to new spaces and equipment in 2023, in addition to another 167 for preclinical research in the 2024/29 period.
Leader in the pharmaceutical industry
The choice of Madrid reinforces its position as the epicenter of the pharmaceutical industry in Spain. The region is home to 78 companies manufacturing these types of products, representing 22% of all companies in this sector in the country. These companies generate an annual global turnover close to 10 billion euros, accounting for almost half of the national exports.
Finally, Díaz Ayuso highlighted that today the region receives 70% of all investment coming to Spain, and «this commitment from Lilly supports our freedom-based policies.» «It is a vote of confidence in the model of the Community of Madrid,» she added. The pharmaceutical sector in Madrid maintains 17,320 jobs in the Community of Madrid, a figure that has grown by 3% compared to 2024, and nearly 30% since the start of the COVID-19 pandemic. It is also a leader in Europe in clinical trials and a global reference in biopharmaceutical innovation, with an advanced healthcare network, research centers, and highly qualified professionals that position it as a preferred destination for investments in this field.
Deja una respuesta